



University
of Glasgow

School of Health
& Wellbeing



Using Mixed-Methods Development-Focused HTA and NPV Calculations to Guide Further Investment and R&D: A Value Proposition for Biosensor-Integrated Arteriovenous Grafts

Samuel Owusu Achiaw, MBChB, MPH

Neil Hawkins, MSc, MBA, PhD

Olivia Wu, MSc, PhD

John Mercer, PhD




HeHTā

HEALTH ECONOMICS AND HEALTH TECHNOLOGY ASSESSMENT



Background

- The arteriovenous graft (AVG) is one of the main options for hemodialysis vascular access.
- Current grafts have high rates of stenosis, i.e. narrowing of the graft lumen, leading to poor functionality.



- Currently in preclinical development, the smart AVG will use impedance spectroscopy to detect arteriovenous graft stenosis (*surveillance use case*) and electrically induce apoptosis to treat stenosis (*interventional use case*). Both functions have only been demonstrated in-vitro¹⁻³ but the clinical value proposition is yet to be established.


- *Using a mixed methods approach, including qualitative methods, decision-analytic modelling, and risk-adjusted net present value (rNPV) analysis, this study explores the value of the smart AVG to guide further research, development and investment.*

- *Qualitative Stakeholder Engagement*




- A stakeholder engagement was conducted with clinicians in the US and UK. Clinicians included interventional cardiologists, a peripheral endovascular specialist, an interventional nephrologist and a vascular surgeon.
- Clinicians expressed their views on if and how the technology may alter clinical pathways in the wake of arteriovenous graft stenoses.

- ***Decision Analytic Modelling***



- Cost-utility analysis (decision tree and Markov model)
- Compared the smart AVG with currently used AVGs (expanded polytetrafluoroethylene (ePTFE) grafts)
- Analysis estimated the incremental net monetary benefit (INMB) of the smart AVG over the ePTFE graft for assumed levels of smart AVG effectiveness.
- A US Medicare perspective was used over a 62-month horizon.
- Model parameters were derived from relevant literature.

- ***Risk-adjusted Net Present Value***



- Using the INMB as the unit cost of the smart AVG, the rNPV and hence the commercial viability of the device was estimated over an assumed developmental lifespan (12 years) up to 10 years of sales.
- $rNPV = \text{Discounted future cash inflow} - \text{Discounted future cash outflow}$.
- Cash flows were adjusted by the probability of success at the end of each developmental stage.
- The average cost, duration and probability of success of Class III FDA devices were used. Market size estimates were based on data from the US renal data system with assumptions made for market penetration.

- Stakeholder engagement revealed difficulty in establishing the current value of the surveillance use case due to the lack of well-established and effective interventions for preclinical stenosis, i.e., stenosis without clinical signs.
- Based on this, the cost-utility analysis focused on the interventional use case and estimated economically justifiable prices at assumed levels of effectiveness.
- Using these prices, rNPVs were estimated in the final stage.

	Item	Estimate
	Target Weighted average cost of capital	10.4%
	Assumed smart AVG effectiveness	60%
Revenues	Unit Price	\$22,832
	Unit Cost of Goods	\$100
	S & G Costs as a percentage of Sales Revenue	30%
	Total Forecast Unit Sales 2035-2044	130,368
	Net revenue if successful	\$2,070,523,018
	Overall Probability of Success	13.7%
	Probability Success Weighted Net Revenue	\$284,652,009
	Discount Factor for Future Sales	81.6%
	Discounted Total Revenue	\$52,477,862
Cost of Development	Probability Weighted Development Costs	\$48,768,344
	Discount Factor for Future Development Costs	31.5%
	Discounted Total Costs	\$33,412,169
Risk-adjusted NPV		\$19,065,693

Table 1. An example of rNPV calculation for an assumed level of effectiveness of the smart AVG for an interventional use case.

Smart AVG effectiveness was expressed as percentage reductions in graft failure from stenosis when compared to ePTFE grafts. Unit price was the INMB estimated from the cost-utility analysis using a willingness-to-pay threshold of \$100,000 per QALY. The cost of goods was assumed as the additional manufacturing cost of the smart AVG over that of the ePTFE graft.

Table 2. Two-way sensitivity table showing rNPV as smart AVG effectiveness and cumulative probability of developmental success are varied

Cumulative probability of success	Effectiveness of Smart AVG							
		0%	20%	30%	41%	50%	60%	80%
	0.0%	-\$12,277,791	-\$12,277,791	-\$12,277,791	-\$12,277,791	-\$12,277,791	-\$12,277,791	-\$12,277,791
	5.0%	-\$27,051,297	-\$21,349,591	-\$18,255,090	-\$14,644,392	-\$11,516,962	-\$7,845,256	\$183,407
	10.0%	-\$31,211,533	-\$19,808,121	-\$13,619,119	-\$6,397,723	-\$142,863	\$7,200,550	\$23,257,874
	13.7%	-\$33,742,589	-\$18,065,371	-\$9,556,836	\$371,018	\$8,970,093	\$19,065,693	\$41,141,032
	20.0%	-\$37,413,498	-\$14,606,675	-\$2,228,671	\$12,214,121	\$24,723,840	\$39,410,666	\$71,525,316
	25.0%	-\$40,039,990	-\$11,531,460	\$3,941,045	\$21,994,534	\$37,631,683	\$55,990,216	\$96,133,528
	30.0%	-\$42,481,010	-\$8,270,774	\$10,296,231	\$31,960,419	\$50,724,998	\$72,755,237	\$120,927,211
	35.0%	-\$44,782,310	-\$4,870,369	\$16,791,138	\$42,066,024	\$63,958,032	\$89,659,977	\$145,860,614
	40.0%	-\$46,973,332	-\$1,359,685	\$23,396,323	\$52,281,907	\$77,301,345	\$106,674,997	\$170,904,296
	45.0%	-\$49,074,340	\$2,241,013	\$30,091,521	\$62,587,803	\$90,734,671	\$123,780,030	\$196,037,991
	50.0%	-\$51,099,995	\$5,917,064	\$36,862,074	\$72,969,054	\$104,243,351	\$140,960,416	\$221,247,040


A two-way sensitivity analysis was conducted for varying levels of smart AVG effectiveness and cumulative probability of developmental success. Using the average cumulative probability of success for the development of a Class III device (13.7%) as cited by Sertkaya et al.⁴ a minimum effectiveness level of 41% was necessary for a cost-effective smart AVG that yields a positive rNPV.

- This multi-stage approach assesses the value of a new technology by identifying under which conditions (such as clinical study success, appropriate discount rates, potential market size and product penetration, and assumptions associated with cost-effectiveness modelling and reimbursement) investment in R&D may be regarded as commercially attractive.



University
of Glasgow

School of Health
& Wellbeing



THANK YOU!

samuel.owusuachiaw@glasgow.ac.uk



@UofGHEHTA

@UofGSHW